About Biocon Our Business Research & Development Biocon's Technology Investors Media Careers CSR
  Press Releases
  Download Center
  Video Gallery
  Photo Gallery
  Media Contacts

Company Statement

Biocon Retains Economic Interest in Global Commercialization of Hulio®, (biosimilar Adalimumab) in-licensed by Mylan

Bengaluru, India, May 07, 2019

Following the successful approval and European launch of Hulio®, (biosimilar Adalimumab) in-licensed by our partner Mylan from Fujifilm Kyowa Kirin Biologics, the commercialization rights have been extended from Europe to Global Markets.

Biocon, under the terms of its global partnership with Mylan for monoclonal antibodies, retains its economic interest in this expanded in-licensing arrangement and will gain a share of profits from Global Markets.

Biocon is committed to enable patient access to affordable biosimilars and this partnership accelerates that process.

- Biocon Spokesperson

<< Back




Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved